Journal article

A potential role for N-acetylcysteine in the management of methamphetamine dependence

Rebecca McKetin, Olivia M Dean, Amanda L Baker, Greg Carter, Alyna Turner, Peter J Kelly, Michael Berk

Drug and Alcohol Review | WILEY | Published : 2017


Methamphetamine dependence is a growing problem in Australia and globally. Currently, there are no approved pharmacotherapy options for the management of methamphetamine dependence. N-acetylcysteine is one potential pharmacotherapy option. It has received growing attention as a therapy for managing addictions because of its capacity to restore homeostasis to brain glutamate systems disrupted in addiction and thereby reduce craving and the risk of relapse. N-acetylcysteine also has antioxidant properties that protect against methamphetamine-induced toxicity and it may therefore assist in the management of the neuropsychiatric and neurocognitive effects of methamphetamine. This commentary over..

View full abstract

University of Melbourne Researchers


Funding Acknowledgements

Michael Berk has received grant support from Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Meat and Livestock Board, Novartis, Mayne Pharma and Servier; has been a speaker for AstraZeneca, Bristol- Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth; and has served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck and Servier. Other authors have no conflicts to declare.